RPG Life Sciences Q1 Standalone Net Profit Rises to ₹30.6 Crore vs ₹26.3 Crore

Market snapshot: RPG Life Sciences Limited delivered a robust financial performance for the first quarter of FY27 (ended June 30, 2026), reporting a standalone net profit of ₹30.6 crore, marking a 16.35% growth compared to ₹26.3 crore in the corresponding quarter of the previous year. This growth was driven by a strong topline expansion and operating efficiency, highlighted by a 15.8% increase in revenue from operations to ₹195.7 crore.

Data Snapshot

• Standalone net profit grew 16.35% YoY to ₹30.6 crore in Q1 FY27 from ₹26.3 crore in Q1 FY26 (derived: ₹30.6 cr vs ₹26.3 cr).
• Revenue from operations increased 15.8% YoY to ₹195.7 crore from ₹168.9 crore in Q1 FY26.
• EBITDA grew 17.9% YoY to ₹48.0 crore from ₹40.7 crore, with EBITDA margins expanding by 40 basis points to 24.5%.
• The Domestic Formulations segment expanded 14.8% YoY, outperforming the Indian Pharma Market benchmark growth of 11.6%.
• The API business delivered a strong turnaround of 35.6% YoY growth during the quarter.

What's Changed

• Standalone net profit grew 16.35% YoY to ₹30.6 crore, reversing the Q1 FY26 trend where standalone profit fell 1.8% YoY to ₹26.3 crore.
• EBITDA margin expanded to 24.5% (+40 bps YoY) compared to 24.1% in Q1 FY26, driven by operating discipline and strategic launches.
• The Active Pharmaceutical Ingredients (API) business recorded a strong turnaround of 35.6% YoY growth, supported by the recovery of its manufacturing unit back to full operations.

Key Takeaways

• Domestic Formulations segment grew at 14.8% YoY, outperforming the Indian Pharma Market industry benchmark growth rate of 11.6%.
• API segment achieved a 35.6% rebound following past operational delays, indicating restored capacity and operational efficiency.
• Topline expansion is well supported across portfolios: International Formulations grew 7.7% and Domestic Formulations remains the core growth driver.
• RPG Life Sciences entered the list of Top 50 Indian pharmaceutical companies as of June 2026.

SAHI Perspective

RPG Life Sciences continues to demonstrate robust operational execution, particularly in its Domestic Formulations segment, which remains the company’s primary margin anchor. The sharp 35.6% rebound in the API business is a critical positive, signaling that past disruptions at its manufacturing facilities are fully resolved. While international formulations grew at a moderate 7.7%, the company's focus on high-margin chronic segments and strategic launches, like Naprosyn ES, positions it well to sustain a higher EBITDA margin profile of ~24.5% going forward.

Market Implications

The strong performance across all business segments is likely to be viewed positively by the street. With the stock trading near its 52-week highs and enjoying an exceptional Relative Strength Rating, these results validate the premium valuation multiple. Consistent market-beating domestic formulations growth and the operational restoration of the API business provide a clear runway for high-quality earnings growth.

Trading Signals

Market Bias: Bullish

Standalone net profit rose 16.35% YoY to ₹30.6 crore alongside a healthy 15.8% growth in operations, supported by a significant 35.6% rebound in the API segment and outperformance in Domestic Formulations.

Overweight: Pharmaceuticals, Healthcare

Trigger Factors:

• Sustained API segment growth of >30% over consecutive quarters.
• Market absorption and sales trajectory of the newly launched Naprosyn ES.
• Continuation of Domestic Formulations outperforming the broader Indian Pharma Market index.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian Pharmaceutical Market registered a growth of 11.6% during the June 2026 quarter. RPG Life Sciences continues to outperform this benchmark, registering 14.8% growth in its Domestic Formulations segment. The broader sector faces persistent cost pressures and regulatory scrutiny, but niche players like RPG Life Sciences are carving out high-margin niches through complex and value-added product launches and asset-light marketing collaborations.

Key Risks to Watch

• Any future operational delays or regulatory disruptions at manufacturing plants.
• Raw material price volatility affecting active pharma ingredients sourcing costs.
• Slower-than-expected pick-up of new therapeutic launches like Naprosyn ES.

Recent Developments

On July 13, 2026, RPG Life Sciences entered into an exclusive partnership with Archerchem Healthcare to launch Naprosyn ES in India. Naprosyn ES is a fixed-dose combination of Naproxen and Esomeprazole, targeting patients on long-term NSAID therapy who face elevated risk of gastrointestinal complications. Additionally, at its AGM on July 23, 2026, shareholders approved a final dividend of ₹24 per equity share (300%) of face value ₹8 each for FY26.

Closing Insight

RPG Life Sciences has successfully kicked off FY27 with balanced growth across its formulations and API portfolios. By combining industry-beating domestic growth with a restored API segment, the company continues to demonstrate high-quality operating leverage and resilient profitability, cementing its position as a high-performing mid-cap pharma player.

High Performance Trading with SAHI.